Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objectives of the study are:
-To evaluate the long-term safety and tolerability of MT-1303 in subjects with moderate to severe active Crohn's Disease（CD）
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MT-1303 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MT-1303 | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Subjects with Adverse Events | 36 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Investigational site | City Name | Czechia | ||||
| Investigational site |
Not provided
| ID | Term |
|---|---|
| D003424 | Crohn Disease |
| ID | Term |
|---|---|
| D015212 | Inflammatory Bowel Diseases |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000624397 | amiselimod |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| City Name |
| France |
| Investigational site | City Nmae | Germany |
| Investigational site | City Nmae | Hungary |
| Investigational site | City Name | Israel |
| Investigational site | City Name | Italy |
| Investigational site | City Nmae | Japan |
| Investigational site | City Name | Netherlands |
| Investigational site | City Name | Poland |
| Investigational site | City Name | Slovakia |
| Investigational site | City Name | Ukraine |
| D007410 | Intestinal Diseases |